Clinical Programs

The core technology behind Mitotech products is based on a novel class of small molecules – mitochondria addressed cardiolipin peroxidation inhibitors. Our lead compound SkQ1 is being developed in several drug formulations covering a variety of therapeutic areas and methods of administration. The most advanced SkQ1-based drug product in Mitotech’s pipeline is Visomitin™ which reached Phase III stage in the U.S. for dry eye syndrome. Visomitin™ already received marketing approval for dry eye syndrome in Russia. Other indications include other ophthalmic, neurodegenerative, cardiovascular and metabolic disorders and are at earlier stages of clinical development.

US

Drug/Indication
 
Pre-clinical
Phase 1
Phase 2
Phase 3

Visomitin™ (SkQ1 eye drops)

Dry Eye
Dry Eye
Phase III ready
Uveitis
Uveitis
Phase II ready
Dry AMD
Dry AMD
Phase II ready

Plastomitin™ (SkQ1 pill)

Multiple Sclerosis
Multiple Sclerosis
Pre-clinical Completed
Acute Kidney Injury
Acute Kidney Injury
Pre-clinical Completed
Barth Syndrome
Pre-clinical Completed

Russia

Drug/Indication
 
Pre-clinical
Phase 1
Phase 2
Phase 3

Visomitin™ (SkQ1 eye drops)

Dry Eye
Marketing approval received
LHON
Phase II completed
Dry AMD
Pre-clinical Completed

Plastomitin™ (SkQ1 pill)

Neurodegeneration
Phase I in progress

Mitotech is committed to adding therapeutic indications that are important for millions of patients worldwide as well as rare genetic disorders to its development pipeline to make sure SkQ1 technology realizes its full pharmaceutical potential.